Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This study aims to examine the delicate management dilemmas precipitated by medication hypersensitivity, emotional volatility, and escalated risk of falls in MSA, accentuating the need for a patient-centered paradigm.

Background: MSA, an acutely progressive neurodegenerative malady, manifests a gamut of motor and non-motor symptoms. Pharmacological regimens frequently culminate in an oversedation conundrum, whereas emotional lability limits psychiatric medication adherence. Moreover, the continual menace of falls, notwithstanding mechanical aids, highlights the inadequacies of extant management protocols. Such predicaments demand the formulation of thoughtful management stratagems to enhance patient prognoses and bolster caregiver support.

Method: Through a qualitative synthesis of patient case reports and a review of the latest literature, this study investigates the efficacy and challenges of existing pharmacological and non-pharmacological interventions in MSA management. This research further explores multidisciplinary approaches, incorporating input from neurology, psychiatry, physical therapy, and occupational therapy.

Results: The study reveals a critical difficulty in the effective management of MSA, particularly in addressing the trifecta of medication sensitivity, emotional lability, and fall risk. Findings highlight the importance of tailored, minimalistic medication regimens and the integration of non-pharmacological strategies such as personalized rehabilitation programs and psychotherapy in mitigating the adverse effects of these challenges.

Conclusion: Effective management of MSA requires a delicate balance between mitigating motor and non-motor symptoms and navigating the adverse effects of treatment strategies. This study advocates for a holistic, multidisciplinary approach that prioritizes patient safety, emotional well-being, and functional independence. Future research should focus on the development of integrated care models to address the multifaceted challenges faced by patients with MSA and their caregivers.

References: 1. Komatsu H, Kato M, Kinpara T, Ono T, Kakuto Y. Possible multiple system atrophy with predominant parkinsonism in a patient with chronic schizophrenia: a case report. BMC Psychiatry. 2018;18:141.
2. Lee S-H, Lee T-W, Lu C-S. A case of early multiple system atrophy unveiled by antidepressant administration. Acta Neuropsychiatrica. 2011;23:139–40.
3. Burns MR, McFarland NR. Current management and emerging therapies in multiple system atrophy. Neurotherapeutics. 2020;17:1582–602.
4. Miki Y, Foti SC, Asi YT, Tsushima E, Quinn N, Ling H, et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain. 2019;142:2813–27.
5. D’Souza GL, K. PN. Rare presentation of hallucinations in cerebellar multisystem atrophy. Int J Res Med Sci. 2020;9:285.
6. Argyropoulos GP, Moore L, Loane C, Roca-Fernandez A, Lage-Martinez C, Butler CR. Emotional lability in hippocampal atrophy due to autoimmune limbic encephalitis. Members’ POSTER Abstracts. BMJ Publishing Group Ltd; 2019. p. A15.2-A16.
7. Coon EA, Ahlskog JE. My treatment approach to multiple system atrophy. Mayo Clin Proc. 2021;96:708–19.

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/multifaceted-challenges-in-multisystem-atrophy-management-medication-sensitivity-emotional-lability-and-increased-fall-risk/